HK Stock Market Move | HUA MEDICINE-B(02552) rose more than 8% as multiple research results of the drug Dorzagliatin appeared at the ADA. The systematic advancement of GK Charger medicine continues.

HUA MEDICINE-B (02552) rose more than 8%, as of the time of publication, it rose by 8.04% to 2.15 Hong Kong dollars, with a trading volume of 3.45 million Hong Kong dollars. In terms of news, recently, Hualeading Medicine announced a series of groundbreaking research results on the global first-in-class glucokinase activator (GKA) dorzagliatin at the 86th Annual Scientific Meeting of the American Diabetes Association (ADA), covering synergistic effects of combination therapy, large-scale real-world evidence, and AI precision diagnosis and treatment tools, further consolidating its global leading position in the field of blood glucose homeostasis research. The results further validate the advantages of dorzagliatin in restoring blood glucose homeostasis from the source and suggest its broad potential in complex metabolic diseases such as type 2 diabetes, metabolic-related fatty liver disease, obesity, MODY2, etc., continuously solidifying the company's leading position in the global blood glucose homeostasis research field. In addition, focusing on the core mechanism of glucokinase (GK), Hua Medicine integrates artificial intelligence (AI), large language models (LLM), and clinical big data, developing AI tools covering efficacy prediction, diabetes remission prediction, single-gene diabetes classification, medical intelligence education, etc. Among them, GK Charger is a medical education platform based on large language models, which can transform complex scientific knowledge into evidence-based content applicable to clinical practice and patients; the efficacy prediction model based on clinical research data of dorzagliatin can predict the response rate of HbA1c and diabetes remission rate after patients receive dorzagliatin; the GK mutation AI analysis system relies on a database of nearly a thousand GK mutations, can complete gene diagnosis and drug response prediction for MODY2 in seconds, with an accuracy rate of 90%.